Skip to content
Dalteparin sodium
Fragmin (dalteparin sodium) is an oligosaccharide pharmaceutical. Dalteparin sodium was first approved as Fragmin on 1994-12-22. It is used to treat myocardial infarction, postoperative complications, pulmonary embolism, thromboembolism, and thrombophlebitis amongst others in the USA. The pharmaceutical is active against antithrombin-III.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
respiratory tract diseasesD012140
cardiovascular diseasesD002318
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Fragmin
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Dalteparin sodium
Tradename
Company
Number
Date
Products
FRAGMINMylanN-020287 RX1994-12-22
9 products, RLD
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
fragminNew Drug Application2020-09-24
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
myocardial infarctionEFO_0000612D009203I21
postoperative complications—D011183—
pulmonary embolismEFO_0003827D011655I26
thromboembolismHP_0001907D013923—
thrombophlebitisHP_0004418D013924—
unstable anginaEFO_1000985D000789I20.0
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
Code
Description
J1645
Injection, dalteparin sodium, per 2500 iu
Clinical
Clinical Trials
45 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FibromyalgiaD005356EFO_0005687M79.1—181—9
SpasmD013035M62.83——1113
PainD010146EFO_0003843R52—1—2—3
Low back painD017116HP_0003419M54.5——11—2
Morbid obesityD009767EFO_0001074———1—1
FatigueD005221HP_0012378R53.83———1—1
SleepD012890GO_0030431———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Post-traumatic stress disordersD013313EFO_0001358F43.1—34——7
Musculoskeletal painD059352——2——2
Muscular diseasesD009135EFO_0002970G72.9——2——2
Nervous system diseasesD009422G00-G99——2——2
Rheumatic diseasesD012216M79.0——2——2
Musculoskeletal diseasesD009140——2——2
Myofascial pain syndromesD009209EFO_1001054——2——2
Neuromuscular diseasesD009468EFO_1001902G70.9——2——2
Acute painD059787R52——1——1
Neck painD019547HP_0030833M54.2——1——1
Show 2 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Sleep initiation and maintenance disordersD007319F51.01—1———1
Covid-19D000086382U07.1—1———1
Post-acute covid-19 syndromeD000094024—1———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients—3———14
DepressionD003863F33.91————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Migraine disordersD008881EFO_0003821G43————11
HeadacheD006261HP_0002315R51————11
ArthritisD001168EFO_0005856M05-M14————11
TendinopathyD052256EFO_1001434M77.9————11
SynovitisD013585EFO_0008997M67.5————11
RadiculopathyD011843M54.1————11
GoutD006073EFO_0004274M10————11
Ankle fracturesD064386S82.5————11
BunionD000071378M21.61————11
Hammer toe syndromeD037801EFO_1001336M21.53————11
Show 3 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameDALTEPARIN SODIUM
INNdalteparin sodium
Description
Dalteparin is a low molecular weight heparin. It is marketed as Fragmin. Like other low molecular weight heparins, dalteparin is used for prophylaxis or treatment of deep vein thrombosis and pulmonary embolism to reduce the risk of a stroke or heart attack. Dalteparin acts by potentiating the activity of antithrombin III, inhibiting formation of both Factor Xa and thrombin. It is normally administered by self-injection.
Classification
Oligosaccharide
Drug classheparin derivatives and low molecular weight (or depolymerized) heparins
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)—
Identifiers
PDB—
CAS-ID—
RxCUI67109
ChEMBL IDCHEMBL1201460
ChEBI ID—
PubChem CID—
DrugBankDB06779
UNII ID12M44VTJ7B (ChemIDplus, GSRS)
Target
Agency Approved
SERPINC1
SERPINC1
Organism
Homo sapiens
Gene name
SERPINC1
Gene synonyms
AT3
NCBI Gene ID
Protein name
antithrombin-III
Protein synonyms
serine (or cysteine) proteinase inhibitor, clade C (antithrombin), member 1, Serpin C1, serpin peptidase inhibitor clade C member 1, serpin peptidase inhibitor, clade C (antithrombin), member 1
Uniprot ID
Mouse ortholog
Serpinc1 (11905)
antithrombin-III (P32261)
Alternate
No data
Variants
Clinical Variant
No data
Financial
Fragmin - Pfizer
$
€
£
₣
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 264 documents
View more details
Safety
Black-box Warning
Black-box warning for: Fragmin
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
9,511 adverse events reported
View more details